Foghorn Therapeutics Inc (FHTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Foghorn Therapeutics Inc (FHTX) has a cash flow conversion efficiency ratio of 0.233x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.90 Million) by net assets ($-81.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see FHTX market cap for the company's overall valuation and market capitalisation.
Foghorn Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Foghorn Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Foghorn Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Foghorn Therapeutics Inc ranked by their cash flow conversion efficiency. See Foghorn Therapeutics Inc cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Halla Holdings Corp
KO:060980
|
0.018x |
|
Immersion Corporation
NASDAQ:IMMR
|
0.148x |
|
BT Group Plc
LSE:BT-A
|
0.297x |
|
Armada Acquisition Corp. II
NASDAQ:XRPN
|
0.002x |
|
Pacific Smiles Group Ltd
AU:PSQ
|
0.382x |
|
JNK India Ltd
NSE:JNKINDIA
|
0.018x |
|
J.G.CHEMICALS LIMITED
NSE:JGCHEM
|
0.066x |
|
Tianyu Ecology & Landscape Co
SHG:603717
|
0.089x |
Annual Cash Flow Conversion Efficiency for Foghorn Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Foghorn Therapeutics Inc from 2018 to 2025. View Foghorn Therapeutics Inc (FHTX) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-108.50 Million | $-86.10 Million | 0.794x | -64.02% |
| 2024-12-31 | $-45.53 Million | $-100.41 Million | 2.205x | +44.14% |
| 2023-12-31 | $-77.19 Million | $-118.11 Million | 1.530x | -99.91% |
| 2022-12-31 | $112.00K | $193.61 Million | 1728.679x | +333351.39% |
| 2021-12-31 | $96.87 Million | $-50.25 Million | -0.519x | -142.38% |
| 2020-12-31 | $146.19 Million | $-31.29 Million | -0.214x | -140.65% |
| 2019-12-31 | $-88.02 Million | $-46.34 Million | 0.526x | -8.71% |
| 2018-12-31 | $-39.27 Million | $-22.65 Million | 0.577x | -- |
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mu… Read more